156 related articles for article (PubMed ID: 25484091)
21. Chemotherapeutic drug selectivity between wild-type and mutant BRaf kinases in colon cancer.
Zhang J; Ji T
J Mol Model; 2017 Jan; 23(1):1. PubMed ID: 27921184
[TBL] [Abstract][Full Text] [Related]
22. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
23. Vemurafenib for the treatment of BRAF mutant metastatic melanoma.
Martin-Liberal J; Larkin J
Future Oncol; 2015; 11(4):579-89. PubMed ID: 25686114
[TBL] [Abstract][Full Text] [Related]
24. Vemurafenib for the treatment of melanoma.
Jordan EJ; Kelly CM
Expert Opin Pharmacother; 2012 Dec; 13(17):2533-43. PubMed ID: 23094782
[TBL] [Abstract][Full Text] [Related]
25. BH3-mimetic gossypol-induced autophagic cell death in mutant BRAF melanoma cells with high expression of p21Cip¹.).
Jang GH; Lee M
Life Sci; 2014 Apr; 102(1):41-8. PubMed ID: 24625733
[TBL] [Abstract][Full Text] [Related]
26. Targeting mitochondrial metabolism by inhibiting autophagy in BRAF-driven cancers.
Strohecker AM; White E
Cancer Discov; 2014 Jul; 4(7):766-72. PubMed ID: 24860158
[TBL] [Abstract][Full Text] [Related]
27. BRAF-induced tumorigenesis is IKKα-dependent but NF-κB-independent.
Margalef P; Colomer C; Villanueva A; Montagut C; Iglesias M; Bellosillo B; Salazar R; Martínez-Iniesta M; Bigas A; Espinosa L
Sci Signal; 2015 Apr; 8(373):ra38. PubMed ID: 25900832
[TBL] [Abstract][Full Text] [Related]
28. Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.
Peters S; Bouchaab H; Zimmerman S; Bucher M; Gaide O; Letovanec I; Homicsko K; Michielin O
Melanoma Res; 2014 Oct; 24(5):496-500. PubMed ID: 25185693
[TBL] [Abstract][Full Text] [Related]
29. Targeting BRAF in pediatric brain tumors.
Kieran MW
Am Soc Clin Oncol Educ Book; 2014; ():e436-40. PubMed ID: 24857135
[TBL] [Abstract][Full Text] [Related]
30. The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance.
Wroblewski D; Mijatov B; Mohana-Kumaran N; Lai F; Gallagher SJ; Haass NK; Zhang XD; Hersey P
Carcinogenesis; 2013 Feb; 34(2):237-47. PubMed ID: 23087082
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties.
Ott PA; Henry T; Baranda SJ; Frleta D; Manches O; Bogunovic D; Bhardwaj N
Cancer Immunol Immunother; 2013 Apr; 62(4):811-22. PubMed ID: 23306863
[TBL] [Abstract][Full Text] [Related]
32. Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib.
van Tilburg CM; Selt F; Sahm F; Bächli H; Pfister SM; Witt O; Milde T
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29230924
[TBL] [Abstract][Full Text] [Related]
33. Population Pharmacokinetics of Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E-Mutant Astrocytomas.
Wang H; Long-Boyle J; Winger BA; Nicolaides T; Mueller S; Prados M; Ivaturi V
J Clin Pharmacol; 2020 Sep; 60(9):1209-1219. PubMed ID: 32476174
[TBL] [Abstract][Full Text] [Related]
34. Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy.
Robinson GW; Orr BA; Gajjar A
BMC Cancer; 2014 Apr; 14():258. PubMed ID: 24725538
[TBL] [Abstract][Full Text] [Related]
35. Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma.
Guerreschi P; Scalbert C; Qassemyar A; Kluza J; Ravasi L; Huglo D; Martinot-Duquennoy V; Formstecher P; Marchetti P; Mortier L
Melanoma Res; 2013 Oct; 23(5):373-80. PubMed ID: 23852164
[TBL] [Abstract][Full Text] [Related]
36. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
[TBL] [Abstract][Full Text] [Related]
37. Autophagy-related protein expression was associated with BRAF V600E mutation in epilepsy associated glioneuronal tumors.
Shen CH; Zhang YX; Xu JH; Zhu QB; Zhu JM; Guo Y; Ding Y; Wang S; Ding MP
Epilepsy Res; 2017 Sep; 135():123-130. PubMed ID: 28667867
[TBL] [Abstract][Full Text] [Related]
38. BRAF Mutations in CNS Tumors-Prognostic Markers and Therapeutic Targets.
Muniz TP; Mason WP
CNS Drugs; 2023 Jul; 37(7):587-598. PubMed ID: 37268805
[TBL] [Abstract][Full Text] [Related]
39. A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas.
Sun Y; Alberta JA; Pilarz C; Calligaris D; Chadwick EJ; Ramkissoon SH; Ramkissoon LA; Garcia VM; Mazzola E; Goumnerova L; Kane M; Yao Z; Kieran MW; Ligon KL; Hahn WC; Garraway LA; Rosen N; Gray NS; Agar NY; Buhrlage SJ; Segal RA; Stiles CD
Neuro Oncol; 2017 Jun; 19(6):774-785. PubMed ID: 28082416
[TBL] [Abstract][Full Text] [Related]
40. Computational modeling reveals MAP3K8 as mediator of resistance to vemurafenib in thyroid cancer stem cells.
Gianì F; Russo G; Pennisi M; Sciacca L; Frasca F; Pappalardo F
Bioinformatics; 2019 Jul; 35(13):2267-2275. PubMed ID: 30481266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
